Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of “Buy” from Brokerages

by · The Cerbat Gem

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) have been given an average rating of “Buy” by the eight ratings firms that are covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $71.40.

A number of analysts have weighed in on ARCT shares. Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. HC Wainwright reiterated a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a report on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Finally, Leerink Partners started coverage on shares of Arcturus Therapeutics in a research note on Monday, August 12th. They set an “outperform” rating and a $70.00 price target for the company.

Get Our Latest Analysis on ARCT

Arcturus Therapeutics Price Performance

Shares of NASDAQ:ARCT opened at $20.37 on Tuesday. The firm has a fifty day simple moving average of $20.61 and a two-hundred day simple moving average of $24.21. Arcturus Therapeutics has a 52 week low of $17.26 and a 52 week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.44. The company had revenue of $41.67 million for the quarter, compared to analysts’ expectations of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.29% and a negative net margin of 36.39%. During the same period in the previous year, the firm posted ($0.61) earnings per share. On average, equities research analysts predict that Arcturus Therapeutics will post -2.6 EPS for the current year.

Insider Buying and Selling

In other news, COO Pad Chivukula sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at approximately $9,037,533.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 15.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of large investors have recently modified their holdings of ARCT. Quest Partners LLC boosted its holdings in Arcturus Therapeutics by 437.1% in the third quarter. Quest Partners LLC now owns 19,810 shares of the biotechnology company’s stock valued at $460,000 after purchasing an additional 16,122 shares during the last quarter. Royce & Associates LP boosted its stake in shares of Arcturus Therapeutics by 18.3% during the 3rd quarter. Royce & Associates LP now owns 155,803 shares of the biotechnology company’s stock worth $3,616,000 after acquiring an additional 24,085 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Arcturus Therapeutics by 45.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock valued at $52,819,000 after acquiring an additional 712,650 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Arcturus Therapeutics in the 3rd quarter valued at about $544,000. Finally, ARK Investment Management LLC raised its holdings in Arcturus Therapeutics by 6.9% in the 3rd quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock worth $48,765,000 after purchasing an additional 136,074 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

(Get Free Report

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

Further Reading